Private equity firm Nordic Capital acquired an 80% stake in Danish proteomics company Evosep to accelerate the company’s shift from research workflows into translational and clinical markets. Evosep’s standardized liquid chromatography technology targets high‑throughput, high‑sensitivity LC‑MS proteomics workflows used increasingly in pharma for targeted protein panels and clinical testing. CEO Morten Bern said the investment will help Evosep move into pharmaceutical and clinical-lab applications, where demand for proteoform‑level assays and higher throughput is rising. Nordic Capital’s history of investing in translational diagnostics and clinical tools was cited as a strategic fit. The deal highlights growing investor interest in scaling mass‑spectrometry‑based proteomics beyond discovery into regulated clinical and laboratory‑developed tests, where throughput and standardization remain the main obstacles to broader adoption.